COPD: Management, Latest Guidelines & Harrison's Key Points

1. DEFINITION & EPIDEMIOLOGY

2. DIAGNOSIS

3. GOLD ABE ASSESSMENT TOOL (Harrison's 22E Fig. 303-5)

GOLD 2026 key change: Group E threshold is now ≥1 moderate/severe exacerbation (previously ≥2 moderate or ≥1 hospitalization). This lowers the bar for triple therapy initiation.

4. PHARMACOTHERAPY (Harrison's 22E + GOLD 2025/2026)

Bronchodilators (cornerstone of therapy)

• Salbutamol/albuterol (SABA), ipratropium (SAMA)
• For acute symptom relief

• Tiotropium, umeclidinium, glycopyrronium, aclidinium, revefenacin
• Reduce symptoms + exacerbations (superior to LABA alone)
• Side effect: dry mouth

• Salmeterol, formoterol, indacaterol, olodaterol, vilanterol, arformoterol
• Symptomatic benefit + exacerbation reduction
• Side effects: tremor, tachycardia

Inhaled Corticosteroids (ICS)

• Never used as monotherapy in COPD
• Role: reduce exacerbations, not primarily for symptoms
• Blood eosinophil count (BEC) guides use:
  • BEC <100/µL: no benefit
  • BEC 100-300/µL: add ICS if ongoing exacerbations on dual therapy
  • BEC ≥300/µL: ICS recommended from the start in Group E
• Triple therapy (LABA + LAMA + ICS) reduces mortality in selected patients
• Risks: oropharyngeal candidiasis, pneumonia, bone density loss, cataracts
• ICS withdrawal in stable patients without exacerbations is safe (minor FEV1 decline possible)

PDE4 Inhibitors

• Roflumilast (oral): reduces exacerbations in severe COPD with chronic bronchitis + prior exacerbation history; modest effect on airflow; SE: nausea, diarrhea, weight loss
• Ensifentrine (inhaled PDE3/4 inhibitor - GOLD 2025 NEW): first new drug class in 30 years; nebulized; reduces dyspnea and exacerbations

Biologics (NEW - GOLD 2025/2026)

• Dupilumab (IL-4/IL-13 antagonist): approved for COPD with chronic bronchitis; reduces exacerbations; first approved biologic for COPD
• Mepolizumab (IL-5 antagonist - GOLD 2026 NEW): for eosinophilic COPD (can be used with or without chronic bronchitis); dosed less frequently than dupilumab

Methylxanthines

• Theophylline: modest bronchodilator effect; narrow therapeutic window; may benefit OSA-COPD overlap
• Role is secondary; used when inhaled therapy is not possible/affordable

Macrolide Antibiotics

• Azithromycin daily: reduces exacerbation frequency in patients with history of exacerbations in past 6 months; chosen for anti-inflammatory + antimicrobial properties
• Risks: hearing loss, cardiac arrhythmia (QT prolongation), antimicrobial resistance

Mucolytics

• N-acetylcysteine, erdosteine: modest reduction in exacerbation frequency in patients not on ICS

5. NON-PHARMACOLOGICAL MANAGEMENT

Smoking Cessation (MOST IMPORTANT - improves survival)

• Nicotine replacement therapy (patch, gum, lozenge, inhaler, nasal spray)
• Varenicline (nicotinic receptor partial agonist) - most effective
• Bupropion
• Counseling + pharmacotherapy combination has greatest success

Oxygen Therapy

• Long-term O2 (LTOT): improves survival when resting PaO2 ≤55 mmHg, or PaO2 56-60 mmHg with polycythemia/cor pulmonale
• Goal: SpO2 88-92% (avoid hypercapnia)
• Does NOT benefit patients with moderate resting desaturation (PaO2 56-65 mmHg) - LOTT trial

Pulmonary Rehabilitation

• Improves dyspnea, exercise capacity, and quality of life
• Reduces hospitalizations post-exacerbation
• Indicated for all patients with mMRC ≥2 or CAT ≥10

Lung Volume Reduction Surgery (LVRS)

• Improves survival in upper-lobe predominant emphysema with low exercise capacity (NETT trial)
• Bronchoscopic valve placement (endobronchial valves): for patients not fit for surgery

Vaccination (GOLD 2025 updated schedule)

• Influenza - annual
• Pneumococcal (PCV15/PCV20 + PPSV23)
• COVID-19 (SARS-CoV-2)
• RSV vaccine (newly added)
• Tdap (if not vaccinated as adolescent)
• Herpes zoster vaccine

Non-Invasive Positive Pressure Ventilation (NIPPV)

• Acute: NIV/BiPAP in exacerbations with pH <7.35 and PCO2 >45 mmHg
• Chronic: reduces mortality in severe hypercapnia (PaCO2 >52 mmHg at rest)

Lung Transplantation

• For end-stage COPD (GOLD 3-4, BODE index ≥7, severe hypercapnia, hospitalized exacerbations)

6. EXACERBATION MANAGEMENT (Harrison's 22E)

Outpatient Management (mild-moderate)

• Increase bronchodilator frequency (SABA ± SAMA)
• Short course oral corticosteroids (5 days prednisone 40 mg/day)
• Antibiotics if purulent sputum/respiratory acidosis: amoxicillin-clavulanate, azithromycin, doxycycline, fluoroquinolones

Inpatient Indications

• Respiratory acidosis (pH <7.35, PCO2 >45)
• New/worsening hypoxemia
• Severe underlying COPD
• Significant comorbidities
• Inability to manage at home

Hospital Management (Goldman-Cecil Table 76-3)

• Controlled O2: target SpO2 88-92%
• Systemic corticosteroids: 5-day course (equivalent outcomes to 14 days)
• Antibiotics if indicated
• NIV/BiPAP first-line for hypercapnic respiratory failure (pH 7.25-7.35)
• Intubation if NIV fails or severe acidosis

7. HARRISON'S 22E KEY POINTS (COPD Chapter 303)

1. Three survival-improving interventions: smoking cessation, LTOT in hypoxemic patients, LVRS in selected emphysema patients
2. Triple inhaled therapy (LABA+LAMA+ICS) reduces mortality in selected COPD patients
3. ICS benefit is eosinophil-dependent - BEC <100 = no benefit; BEC ≥300 = start with triple therapy
4. Dual bronchodilators (LABA+LAMA) are first-line for symptomatic Group B/E patients - superior to monotherapy
5. Macrolide prophylaxis: azithromycin daily reduces exacerbations but monitor for QT prolongation and hearing loss
6. Oral steroids are NOT recommended for long-term COPD management (unfavorable risk/benefit ratio)
7. Exacerbation predictor: single greatest risk for hospitalization = prior hospitalization for exacerbation
8. Pulmonary embolism must be considered in exacerbations (increased incidence)
9. ASTHMA-COPD Overlap (ACO): requires ICS - never withhold in eosinophilic features
10. Chronic hypercapnic COPD: nocturnal NIV can improve survival

8. LATEST UPDATES (GOLD 2025/2026)

9. SIMPLIFIED MANAGEMENT FLOWCHART

SUSPECTED COPD
      │
      ▼
Spirometry (post-BD FEV1/FVC < 0.7)
      │
      ▼
CONFIRMED COPD
      │
      ├──── Assign GOLD Grade (1-4) by FEV1%
      │
      ▼
ABE GROUP ASSESSMENT
      │
      ├── Exacerbations ≥1 moderate/severe or ≥1 hospitalization? ──► GROUP E
      │                                                                    │
      ├── 0 exacerbations + mMRC 0-1 / CAT <10 ──────────────────── GROUP A
      │                                                                    │
      └── 0 exacerbations + mMRC ≥2 / CAT ≥10 ──────────────────── GROUP B
      
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
INITIAL PHARMACOTHERAPY:

GROUP A  →  Single bronchodilator (LAMA or LABA)
GROUP B  →  LABA + LAMA (dual bronchodilator)
GROUP E  →  LABA + LAMA ± ICS (add ICS if BEC ≥300)

━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
FOLLOW-UP: REASSESS SYMPTOMS & EXACERBATIONS
      │
      ├── Still dyspneic on dual therapy? ──► Review inhaler technique/adherence
      │                                       Consider ensifentrine or triple therapy
      │
      ├── Still exacerbating on dual therapy?
      │       └── BEC ≥100-300 → Add ICS (triple therapy)
      │           BEC <100 → Add roflumilast (if chronic bronchitis)
      │           Consider azithromycin prophylaxis
      │           Consider biologics (dupilumab/mepolizumab if eosinophilic)
      │
      └── STILL SEVERE / GOLD 3-4?
              └── Pulmonary rehab + assess for LVRS / bronchoscopic valves / transplant

━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
NON-PHARMACOLOGICAL (ALL PATIENTS):
  ✓ Smoking cessation (varenicline preferred)
  ✓ Vaccinations (flu, pneumo, COVID, RSV, Tdap, zoster)
  ✓ Pulmonary rehab (mMRC ≥2)
  ✓ LTOT if PaO2 ≤55 mmHg or SpO2 ≤88%

━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
EXACERBATION?
      │
      ├── MILD (home) → SABA ± SAMA + 5-day oral steroids + antibiotics if purulent
      │
      └── SEVERE (hospital) → Controlled O2 (SpO2 88-92%)
                               + IV/oral steroids
                               + Antibiotics
                               + NIV/BiPAP if pH <7.35 & PCO2 >45
                               + Intubate if NIV fails